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Cardiovascular events are a major cause of morbidity and mortality in kidney transplant 
recipients. We conducted a retrospective study using healthcare databases in Ontario, Canada 
to determine whether the incidence of cardiovascular events has changed from 1994 to 2009 
in 4954 kidney transplant recipients. Our primary endpoint was a 3-year composite outcome 
of post-transplant death or cardiovascular event (myocardial infarction, percutaneous 
coronary intervention, coronary artery bypass graft, or stroke). Recipients were older and had 
more baseline co-morbidity in recent eras (1994-1997 vs. 2006-2009: median age 45 vs. 53 
years; coronary artery disease 22% vs. 37%). A total of 445 recipients (9.0%) died or 
experienced a cardiovascular event within 3 years. There was no significant change in the 
composite outcome or death-censored cardiovascular events (p=0.41 and 0.92, respectively) 
over time. Despite transplant centers accepting recipients who are older with more co-
morbidities, the incidence of death or cardiovascular event has remained stable.  
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Chapter 1 : Introduction 
 
1.1   Background 
Compared to dialysis, kidney transplantation improves survival.(1–3) Cardiovascular 
disease accounts for 30% of deaths with a functioning graft and remains the primary 
cause of death in kidney transplant recipients.(4) As described in recent clinical practice 
guidelines, kidney transplant recipients are a high-risk group for cardiovascular 
disease.(5,6) For example, in a retrospective study of 36,000 kidney transplant recipients 
between 1995 and 2000 identified in the United States Renal Data System (USRDS) 
database, 1 in 10 first-time kidney transplant recipients (11%) had a myocardial 
infarction in the subsequent 3 years.(7) In recent years, a greater proportion of individuals 
receiving kidney transplants are older and have more co-morbidities, including pre-
transplant cardiovascular disease and diabetes mellitus.(8) We conducted this study to 
assess whether these secular changes have resulted in an increased risk of cardiovascular 
events after kidney transplantation over time.  
 
1.2   Objectives 
The specific aims of this research project were as follows: 
1) To describe the secular trends in the 3-year cumulative incidence of death or first 
major cardiovascular event after receiving a kidney transplant for recipients from 
1994 to 2009.  
2) To describe the secular trends in the individual components of the above composite 
outcome, specifically, the 3-year cumulative incidence of a) death and b) death-
censored major cardiovascular event in kidney transplant recipients.  
3) To compare the above trends in the kidney transplant recipient population to that in 
the general population over the same time period. 
2 
 
Chapter 2 : Literature Review 
 
2.1   Chronic Kidney Disease (CKD) 
In 2002, the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative 
(NKF-KDOQI) developed a definition and classification system for chronic kidney 
disease (CKD).(9) In these guidelines, CKD was defined based on the presence of kidney 
damage due to structural or functional abnormalities and/or kidney dysfunction as 
measured by a glomerular filtration rate (GFR) of <60 mL/min/1.73 m2 for at least 3 
months (Table 1).  
 
Table 1: Stages of chronic kidney disease.a 
Stage Description GFR (mL/min/1.73 m2) 
1 Kidney damage with normal or high GFR ≥90 
2 Kidney damage with mild decrease in GFR 60-89 
3 Moderate decrease in GFR 30-59 
4 Severe decrease in GFR 15-29 
5 Kidney failure <15 (or RRT) 
a Adapted from the NKF-KDOQI guidelines.(9) 
Abbreviations: GFR, glomerular filtration rate; NKF-KDOQI, National Kidney 
Foundation-Kidney Disease Outcomes Quality Initiative; RRT, renal replacement 
therapy. 
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2.2   End-Stage Renal Disease (ESRD) 
Definition of ESRD 
End-stage renal disease (ESRD) (CKD Stage 5) is defined as either a GFR of 
<15 mL/min/1.73 m2 or the need for renal replacement therapy (RRT; see Section 2.3) for 
symptoms or complications of kidney failure (Table 1).(9) The Canadian Organ 
Replacement Register (CORR) collects information on patients with kidney failure and 
their subsequent treatments.(10) CORR defines ESRD as patients who receive treatment 
for their kidney failure with either ongoing dialysis or a kidney transplant. 
 
Epidemiology of ESRD 
Prevalence is defined as the number of total cases at a point in time divided by the size of 
the overall population. Incidence is defined as the number of new cases during a given 
period divided by the size of the at-risk population. The rate per million population 
(PMP) per year is calculated as (number of cases / population) x 1,000,000. 
According to CORR, in 2012, there were 41,252 prevalent cases of ESRD in 
Canada and this number has increased by 40% from 29,540 in 2003.(10) Older patients 
(≥65 years old) represent approximately 40% of prevalent cases of ESRD and the 
proportion of males is 60%. Diabetes mellitus remains the primary cause of ESRD (27%) 
followed by glomerulonephritis (i.e. inflammation of the kidneys usually due to an 
immunological disease; 22%). 
 In 2012, there were 5431 incident cases of ESRD for an incidence rate of 156 
PMP.(10) Although the incidence rate is higher than it was in 1993 (incidence rate of 101 
PMP), it has remained stable over the last decade (in 2003, incidence rate was 162 PMP).  
Older patients (≥65 years old) represent more than half of new cases each year. The 
primary cause of ESRD is diabetes mellitus accounting for approximately 38% of new 
cases, followed by renal vascular diseases (15%) such as hypertension. 
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2.3   Renal Replacement Therapy (RRT) 
Definition of RRT 
The treatment for patients with kidney failure is commonly referred to as renal 
replacement therapy (RRT). The most common form of RRT is dialysis, which consists 
of either hemodialysis or peritoneal dialysis. Dialysis acts as an artificial kidney, 
removing waste products and excess water from the body. The second form of RRT is 
kidney transplantation for which the organ can be from either a living donor or a 
deceased donor.  
 
Epidemiology of RRT 
Overall, in 2012, the proportion of patients with ESRD on dialysis was 58% (n=23,814) 
of which approximately 50% were on hemodialysis and 10% were on peritoneal 
dialysis.(10) The remaining 42% (n=17,438) of patients with ESRD had a functioning 
kidney transplant and this rate has increased from 222 PMP in 1993 to 500 PMP in 2012. 
The proportions of patients on dialysis (approximately 60%) or with a functioning kidney 
transplant (approximately 40%) have not changed dramatically in the last decade. The 
highest number of kidney transplant surgeries in Canada is performed in Ontario. 
The majority of patients who start treatment for their ESRD are initiated on 
hemodialysis (79%), followed by peritoneal dialysis (18%), then pre-emptive kidney 
transplantation (i.e. receipt of a kidney transplant without receiving dialysis first; 
3%).(10) In Canada, these proportions have remained fairly stable over time from 2003 to 
2012. 




2.4   Outcomes in Dialysis Versus Kidney Transplantation 
There have been many studies comparing the different types of RRT and survival for 
patients with ESRD.(1–3,11) In a longitudinal study by Wolfe et al., kidney transplant 
recipients in the United States (U.S.) had a 2.8-fold higher relative risk of death in the 
first 2 weeks of their surgery compared to patients who remained on the waiting list for a 
transplant.(1) This was likely due to peri-operative surgical risks as well as risks 
associated with initial high-dose immunosuppression used for induction and maintenance 
therapy. At 18 months, the relative risk of death in kidney transplant recipients compared 
to patients on the waiting list was significantly lower (relative risk 0.32; 95% confidence 
interval [CI] 0.30 to 0.35; p<0.001). The survival benefit was observed across all ages 
(including older recipients), both sexes, all races, and for all causes of ESRD but was 
greatest amongst recipients who were younger, Caucasian, or had diabetes mellitus as the 
cause of their ESRD. Similar results were observed in a cohort of patients with ESRD 
from Ontario, Canada.(3) The 5-year patient survival is higher with a kidney from a 
living donor (94%) than with a kidney from a deceased donor (76%) and both are higher 
than remaining on chronic dialysis (60%). In addition to greater long-term survival, 
kidney transplantation is also associated with improved quality of life and lower 
healthcare costs compared to remaining on dialysis.(12–16) For all these reasons, in 
eligible patients with ESRD, kidney transplantation is the preferred treatment modality. 
 
2.5   Cardiovascular Disease in Kidney Transplant 
Recipients 
While the risk of cardiovascular death is significantly lower with kidney transplantation 
compared to dialysis, the risk remains higher than the general population even after 
stratifying by age, sex, and race.(17,18) According to the 2014 United States Renal Data 
System (USRDS) Annual Report, cardiovascular disease remains the primary identified 
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cause of death in kidney transplant recipients.(4) It accounts for almost 30% of deaths 
with a functioning graft. 
Unfortunately, there is limited information regarding the incidence of non-fatal 
cardiovascular events post-transplantation. One study using the USRDS followed almost 
36,000 kidney transplant recipients between 1995 to 2000 and found that the 3-year 
cumulative incidence of post-transplant myocardial infarction was 11%.(7) The 
occurrence of a myocardial infarction predicted graft failure (hazard ratio 1.9; 95% CI 1.6 
to 2.2) and death.  
Another study using the USRDS compared female kidney transplant recipients 
between 1987 to 1994 whose ESRD was due to lupus nephritis (n=946), diabetes mellitus 
(n=5173), or other causes (n=12,733).(19) After a median follow-up of 2.5 years, and 
after adjusting for age and race, the incidence rate of post-transplant myocardial 
infarction was similar in women with lupus nephritis as their cause of ESRD compared to 
women with other causes for ESRD (5.7 per 1000 patient-years for women with lupus 
nephritis vs. 3.1 per 1000 patients years for women with other causes; adjusted hazard 
ratio [aHR] 1.67; 95% CI 0.86 to 3.23; p=0.13). The adjusted incidence rate was highest 
in women with diabetes mellitus as their cause of ESRD compared to women with other 
causes for ESRD (10.0 per 1000 patient-years; aHR 3.31; 95% CI 2.59 to 4.22; 
p<0.0001). These incidence rates in kidney transplant recipients were lower than in the 
women who remained on dialysis.  
Another retrospective cohort study using the Netherlands Organ Transplantation 
Registration database followed 2187 kidney transplant recipients between 1984 to 1997 
and reported that the cumulative incidence of post-transplant cardiovascular events 
(myocardial infarction, percutaneous coronary intervention, coronary artery bypass 
grafting, cerebrovascular accident, and cardiovascular death) was 40%.(20) The 
incidence of cardiovascular events was highest in the first 3 months after transplantation 
(4%). Although the median follow-up was 8 years (interquartile range 4.5 to 11.4), this 
study only included recipients transplanted before 1997 and may not reflect current 
patient characteristics or clinical practice patterns. 
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Similarly, a smaller study from Germany compared 46 patients with type I 
diabetes mellitus who received a kidney transplant between 1978 to 1997 to 46 patients 
with type I diabetes mellitus who were on the waiting list for a transplant but remained on 
hemodialysis.(11) Recipients and dialysis patients were matched 1:1 on age, sex, duration 
of diabetes mellitus, dialysis vintage (duration on dialysis), and waitlist duration. After a 
mean follow-up time of 6 years, kidney transplant recipients had a significantly lower 
risk of myocardial infarction (9% vs. 28%; odds ratio [OR] 0.24; 95% CI 0.07 to 0.81; 
p=0.03) and coronary angioplasty (9% vs. 33%; OR 0.20; 95% CI 0.06 to 0.65; p=0.008) 
compared to hemodialysis patients. 
 
2.6   Cardiac Risk Factors in Kidney Transplant Recipients 
Kidney transplant recipients have a unique combination of traditional cardiovascular risk 
factors and renal-specific cardiovascular risk factors.(21) Traditional cardiovascular risk 
factors include hypertension, diabetes mellitus, hyperlipidemia, smoking, older age, 
obesity, and physical inactivity.(22) Renal-specific associative factors include decreased 
renal function (compared to the general population), immunosuppressive medications, 
episodes of rejection and graft loss, and donor type (living versus deceased 
donors).(20,23,24) These factors are often interrelated and thus, it can be difficult to 
isolate the effects of a single risk factor on cardiovascular outcomes. For example, 
although a kidney transplant improves the recipient’s renal function, there is often 
residual renal impairment that can cause or exacerbate other cardiovascular risk factors 
such as hypertension.(21) In some studies, decreased renal function has been shown to be 
an independent risk factor for cardiovascular disease.(25–28) Similarly, long-term 
immunosuppressive medications, such as steroids and calcineurin-inhibitors, used to 
prevent and treat rejection may cause or worsen hypertension, diabetes mellitus, and renal 
impairment.(23) For these reasons, the Kidney Disease: Improving Global Outcomes 
(KDIGO) guidelines suggest that kidney transplant recipients be considered to be at the 
highest risk for cardiovascular disease.(5) 
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2.7   Secular Trends in Cardiovascular Disease 
There have been several advances in the screening and management of cardiovascular 
disease in the CKD population.(29) In addition to this, the baseline characteristics of 
accepted recipients has changed over time.(8,30) Unfortunately, there is a lack of 
literature regarding how these secular changes have affected cardiovascular outcomes 
after kidney transplantation. One study from 2001 used the USRDS to follow a cohort of 
104,000 patients on the kidney transplant waiting list between 1988 to 1996, of which 
73,707 patients subsequently received a transplant.(31) For transplanted patients, the 5-
year annual adjusted cardiovascular death rate per 1000 patients decreased linearly from 
19.2 in 1989 to 9.1 in 1996. A similar trend for cardiovascular death was seen in 
waitlisted patients (65 in 1989 to 46 in 1996) and in the general population (1.6 in 1989 
to 1.3 in 1996). Thus, cardiovascular death in kidney transplant recipients improved over 
the study period and was lower than those on the waitlist, although it still remained 
higher than the general population.  
In 2007, another study using the Australia and New Zealand Dialysis and 
Transplant (ANZDATA) registry reported trends over time in 6764 kidney transplant 
recipients.(8) From 1993 to 2004, there was a trend towards older recipients, higher 
recipient body mass index, and longer waiting time in recent cohorts. There was also a 
significant increase in baseline recipient co-morbidities including cardiovascular disease 
and diabetes mellitus (assessed at the start of renal replacement therapy). As in the 
previous study, cardiovascular death decreased over time, despite the increase in recipient 
cardiovascular co-morbidities, likely due to improved management over time of 
cardiovascular risk factors and outcomes. In both studies, the outcome of non-fatal 





2.8   Limitations of the Current Literature  
Given the significance of cardiovascular disease in the kidney transplant population, 
information regarding secular trends in cardiovascular outcomes and clinical practices 
would better inform transplant centers and patients. Unfortunately, there are major 
knowledge gaps in the literature and prior studies have significant limitations: 
1) Much of the literature on cardiovascular outcomes using transplant registries focuses 
on cardiovascular mortality rather than non-fatal cardiovascular events. We know little 
about the secular trends in non-fatal cardiovascular events in the kidney transplant 
population despite the increase in recipient cardiovascular co-morbidities over time.(31) 
2) Pre-transplant baseline co-morbidities are often inadequately captured.(8) 
3) Previous studies prior to 2000 have a cohort of recipients that may not be 
representative of the current kidney transplant population.(30)  
4) The largest studies assessing cardiovascular outcomes have used the USRDS (U.S. 
data) and there is a need to understand the trends in a Canadian kidney transplant 
population.(7,31) 
Ontario residents receive universal access to hospital and physician services and coverage 
for medical services are from a single provincial payer system. The unique linked 
healthcare administrative databases at the Institute for Clinical Evaluative Sciences 
(ICES) can be used to generate new information that addresses the limitations of previous 
studies described above. This comprehensive administrative database has been used in 
previous studies to assess trends in renal and cardiovascular outcomes and its strengths 
are internationally recognized.(32,33)  
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Chapter 3 : Methodology 
 
3.1   Design and Setting 
We conducted a population-based retrospective cohort study using linked healthcare 
databases via unique, encoded identifiers held at the Institute for Clinical Evaluative 
Sciences (ICES) in Ontario, Canada. Ontario is the most populous Canadian province 
with approximately 13 million residents who all have universal access to hospital care 
and physician services. The reporting of this study follows guidelines set out for 
observational studies (Appendix 2)(34), and was conducted according to an established 
protocol approved by the research ethics board at Sunnybrook Health Sciences Centre 
(Toronto, Canada). 
 
3.2   Data Sources 
We ascertained baseline characteristics, covariate information, and outcome data from 
records in 4 databases.  
 
Canadian Organ Replacement Register (CORR) Database  
Kidney transplant recipients were identified from the CORR database that captures all 
dialysis and kidney transplant activity in Canada. Compared to information collected at 
the transplant centers, CORR accurately identified kidney transplant recipients with a 
sensitivity of 96% (95% confidence interval [CI] 94% to 97%) and a positive predictive 





Registered Persons Database (RPDB)  
The RPDB captured demographic information such as date of birth, sex, postal code, and 
vital status (such as death).  
 
Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) 
Diagnostic and procedural information during hospital admissions was gathered from the 
CIHI-DAD. Coding of primary and secondary diagnoses and inpatient procedures used 
the 9th version of the International Classification of Disease Canadian Modified system 
(ICD-9 CM) prior to 2002 and the 10th version, Canada (ICD-10 CA) for all diagnoses 
after 2002. We used this database to determine co-morbid conditions prior to 
transplantation, assess cardiovascular outcomes, and identify potential confounders. 
 
Ontario Health Insurance Plan (OHIP) Database 
Physicians in Ontario may submit billing claims for reimbursement to the OHIP using 
diagnostic and fee codes for every inpatient, outpatient, and laboratory service rendered 
to a patient. We used this database to ascertain our primary outcome of cardiovascular 
events.  
 
These databases have been used extensively for research on health outcomes and services 
including studies on cardiovascular disease.(32,36–43) The majority of the data were 
complete with the exception of income (0.3% missing), donor status (1% missing), 
primary cause of end-stage renal disease (ESRD, 8% missing), and race (10% missing). 
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3.3   Population: Kidney Transplant Recipients 
We included all adult recipients who were permanent residents of Ontario and received 
their first kidney-only transplant between January 1, 1994 and December 31, 2009 from 1 
of the 6 major transplant centers in Ontario. The 6 major transplant centers included 
London Health Sciences Centre, St. Joseph’s Healthcare System (Hamilton), University 
Health Network (Toronto), St. Michael’s Hospital (Toronto), Kingston General Hospital, 
and Ottawa General Hospital. Only those kidney transplants performed at The Hospital 
for Sick Children (Toronto) were excluded from the study since our study population 
only consisted of adult kidney transplant recipients. The date of their transplant served as 
the start date for follow-up and was designated the ‘index date’. The year of kidney 
transplantation represented the primary exposure of interest. 
We excluded pediatric recipients (<18 years old) at the time of transplant and 
those who had received a previous organ transplant or a simultaneous multi-organ 
transplant, including kidney-pancreas. Multi-organ transplants are uncommon compared 
to single-organ transplants, with simultaneous kidney-pancreas transplantation 
comprising only 4% of all kidney transplantations done in Ontario in the last 10 
years,(10); cardiovascular outcomes also differ in this population compared to kidney-
only transplantation.(44) A diagram of the kidney transplant recipient cohort selection is 



















3.4   Population: General Population 
We randomly assigned an index date to the entire adult general population in Ontario, 
Canada according to the distribution of index dates in recipients. As in the recipients, we 
excluded residents who were <18 years old on their assigned index date and looked back 
to the beginning of the databases (January 1981 for CORR) to exclude individuals with 
chronic kidney disease (CKD; including those who previously received dialysis or a 
kidney transplant). Kidney transplant recipients were then matched to the general 
population based on age (±1 year), sex, and index date (±6 months) using a 1:4 ratio. No 
recipients were lost in the matching process. 
 
Ontario Kidney Transplant Recipients 
From 1994-2009 
n=6396 
First-time Kidney-only Transplant 
Recipients  
n=4954 
Exclusion Criteria (n=1442): 
 
- <18 years old (n=290) 
- Repeat/previous organ transplant (n=880)  




3.5   Primary Outcome 
The primary outcome was a composite of death or first major cardiovascular event within 
3 years of the index date. A major cardiovascular event was defined as a hospitalization 
where the primary diagnosis was myocardial infarction or ischemic stroke, or evidence of 
a procedural code for percutaneous coronary intervention or coronary artery bypass graft 
surgery. Previous studies in the non-transplant and transplant population have used 
similar cardiovascular outcomes.(20,28,38,45) These diagnostic and procedural codes 
have also been shown to have good validity when compared with chart review 
(Appendix 3). A 3-year follow-up period was chosen in order to compare results to the 
U.S. population where Medicare coverage lasts for only 3 years following 
transplantation. In addition to this, our estimates of cardiovascular incidence could be 
used to inform sample size calculations for future clinical trials. 
 
3.6   Additional Outcomes 
Additional outcomes include the components of the primary outcome analyzed separately 
[i) death and ii) death-censored major cardiovascular event]. We also examined the 
proportion of recipients who received cardiac investigations in the 3 years following 
transplantation. To better inform peri-operative outcomes, we assessed the 30-day 
cumulative incidence of myocardial infarction and ischemic stroke (where hospital 
diagnostic codes were not limited to the primary diagnosis). 
 
3.7   Statistical Analysis 
We conducted all analyses with SAS (Statistical Analysis Software) version 9.3 (SAS 
Institute Inc., Cary, NC). All patients were followed until the outcome of interest or the 
end of the study period (December 31, 2012). We continued to follow all kidney 
transplant recipients even if they experienced graft failure (i.e. recipients were followed 
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for the outcome of interest even if they returned to chronic dialysis or received a re-
transplant during the 3-year follow-up period). 
 
Baseline Characteristics  
Starting the cohort in 1994 allowed for a minimum of 3 years in the look-back window to 
assess for baseline co-morbidities since the CIHI-DAD and OHIP databases were only 
available from 1991 onwards. We categorized the study period into 4-year eras and 
grouped recipients based on their index dates: 1994-1997, 1998-2001, 2002-2005, and 
2006-2009. We reported continuous baseline characteristics as means with standard 
distributions for data that was normally distributed or as medians with interquartile range 
for data that was skewed. Categorical variables were reported as proportions. 
Distributions of baseline characteristics among patients within each era were compared 
using the Chi-square test for categorical variables and ANOVA for continuous variables.  
 
Primary Analyses  
Having the accrual period end in 2009 allowed for a minimum of 3 years of follow-up to 
assess for outcomes since, at the time of analysis, the CIHI-DAD and OHIP databases 
were updated until 2012. We assessed changes in the 3-year cumulative incidence of 
cardiovascular events over time using the Cochran-Armitage test for trend. We reported 
the 95% confidence intervals for the cumulative incidences using the Wilson score 
method. We used Cox proportional hazard analyses to examine the association between 
transplant era and outcome, adjusting for age, sex, and a history of coronary artery 
disease, myocardial infarction, hypertension, and diabetes mellitus at the time of 





Subgroup Analyses  
We repeated the primary analysis in 3 pre-specified subgroups: age at transplantation 
(<65 vs. ≥65 years), sex (males vs. females), and donor type (living vs. deceased; the 1% 
with missing values were not included in the analysis).  
 
Additional Analyses 
We also calculated the incidence rate defined as the rate per 100 person-years of follow-
up. We hypothesized that the incidence rate for the primary outcome would be highest in 
the early peri-operative period. To test this hypothesis, for each era, we performed 
unadjusted serial Poisson models for the following time periods after transplantation: 0-3 
months, 4-12 months, and 13-36 months. Among recipients who experienced an event 
within the first 3 years of transplantation, we also assessed the time to the first qualifying 
event after transplantation. Given the small number of anticipated events for the 30-day 
outcomes of myocardial infarction and ischemic stroke, we reported only the cumulative 




Chapter 4 : Results 
 
4.1   Baseline Characteristics: Kidney Transplant Recipients 
Baseline characteristics for 4954 kidney transplant recipients are presented in Table 2. 
When recipients were followed for a maximum of 3 years, the total follow-up was 14,096 
person-years. Overall, 63% of recipients were males and glomerulonephritis was the 
main cause of end-stage renal disease (ESRD) throughout the study period (35% for the 
entire cohort). The median time on dialysis prior to transplantation was 2 years 
(interquartile range [IQR] 1 to 4) and 41% of recipients received a kidney from a living 
donor.  
The age and co-morbidity of kidney transplant recipients increased during the 
study period. The median age at transplantation increased from 45 years (IQR 35 to 55) 
in 1994-1997 to 53 (IQR 42 to 62) in 2006-2009 (p<0.001). Comparing the era 1994-
1997 to 2006-2009, the proportion of recipients aged 65 years and older increased (from 
5.7% to 17%; p<0.001), as did the proportion of recipients with pre-transplant coronary 
artery disease (from 22% to 37%; p<0.001) and diabetes mellitus (from 21% to 29%; 
p<0.001). The proportion of recipients undergoing cardiovascular investigations in the 3 
years prior to transplantation increased dramatically across the eras. For example, the 
proportion of recipients receiving an echocardiogram increased from 76% in 1994-1997 
to 96% in 2006-2009 (p<0.001). Similarly, the proportion of recipients receiving a pre-
transplant coronary angiogram more than doubled from 9.5% in 1994-1997 to 21% in 




Table 2: Baseline characteristics of kidney transplant recipients in Ontario by era. 











Age (years) 49 [38-59] 45 [35-55] 47 [36-57] 51 [41-60] 53 [42-62] 
<0.001    <65 4345 (88) 988 (94) 1004 (90) 1016 (86) 1337 (83) 
   ≥65 609 (12) 60 (5.7) 106 (9.5) 166 (14) 277 (17) 
Male 3120 (63) 664 (63) 681 (61) 759 (64) 1016 (63) 0.55 
Race       
   Caucasian 3385 (68) 800 (76) 784 (71) 796 (67) 1005 (62) 
<0.001 
   Asian 321 (6.5) 66 (6.3) 67 (6.0) 66 (5.6) 122 (7.6) 
   African-American 276 (5.6) 42 (4.0) 54 (4.9) 69 (5.8) 111 (6.9) 
   Indian 268 (5.4) 52 (5.0) 54 (4.9) 65 (5.5) 97 (6.0) 
   Other 222 (4.5) 22 (2.1) 32 (2.9) 51 (4.3) 117 (7.2) 
   Unknown 482 (9.7) 66 (6.3) 119 (11) 135 (11) 162 (10) 
Income quintileb       
   Lowest 1088 (22) 235 (22) 219 (20) 264 (22) 370 (23) 
0.80    Middle 990 (20) 207 (20) 219 (20) 240 (20) 324 (20) 
   Highest 933 (19) 190 (18) 231 (21) 230 (20) 282 (17) 
Urban residencec 4367 (88) 920 (88) 968 (87) 1051 (89) 1428 (88) 0.15 
Cause of ESRD       
   Glomerulonephritis 1733 (35) 416 (40) 418 (38) 391 (33) 508 (31) 
<0.001 
   Diabetes mellitus 900 (18) 153 (15) 196 (18) 220 (19) 331 (21) 
   Cystic 656 (13) 120 (11) 148 (13) 170 (14) 218 (14) 
   Vascular 518 (10) 92 (8.8) 97 (8.7) 141 (12) 188 (12) 
   Other 759 (15) 158 (15) 167 (15) 201 (17) 233 (14) 
   Unknown 388 (7.8) 109 (10) 84 (7.6) 59 (5.0) 136 (8.4) 
Donor type       
   Deceased 2839 (57) 667 (64) 605 (55) 643 (54) 924 (57) 
<0.001    Living 2048 (41) 348 (33) 492 (44) 531 (45) 677 (42) 
   Unknown 67 (1.4) 33 (3.1) 13 (1.2) 8 (0.7) 13 (0.8) 
Pre-transplant dialysis modality       
   Pre-emptived 446 (9.0) 66 (6.3) 107 (9.6) 101 (8.5) 172 (11) 
<0.001    Hemodialysis 2978 (60) 544 (52) 673 (61) 764 (65) 997 (62) 
   Peritoneal 1530 (31) 438 (42) 330 (30) 317 (27) 445 (28) 




Delayed graft functione 1331 (27) 283 (27) 292 (26) 296 (25) 460 (29) 0.22 
Primary non-functionf 389 (7.9) 88 (8.4) 71 (6.4) 90 (7.6) 140 (8.7) 0.15 
Co-morbiditiesg       
   Coronary artery disease 1527 (31) 235 (22) 312 (28) 410 (35) 597 (37) <0.001 
   Hypertension 3670 (74) 820 (78) 859 (77) 871 (74) 1120 (69) <0.001 
   Diabetes mellitus 1275 (26) 224 (21) 267 (24) 323 (27) 461 (29) <0.001 
   Myocardial infarction 99 (2.0) 13 (1.2) 17 (1.5) 32 (2.7) 37 (2.3) 0.045 
   PCI 115 (2.3) 9 (0.9) 15 (1.4) 30 (2.5) 61 (3.8) <0.001 
   CABG surgery 119 (2.4) 11 (1.0) 21 (1.9) 38 (3.2) 49 (3.0) 0.001 
   Heart failure 692 (14) 171 (16) 160 (14) 167 (14) 194 (12) <0.001 
   Stroke/TIA 67 (1.4) 13 (1.2) 21 (1.9) 14 (1.2) 19 (1.2) 0.37 
Cardiovascular investigationsg       
   Holter monitor 483 (9.7) 83 (7.9) 103 (9.3) 117 (9.9) 180 (11) 0.048 
   Echocardiography 4388 (89) 801 (76) 956 (86) 1081 (91) 1550 (96) <0.001 
   Stress test 3567 (72) 518 (49) 718 (65) 947 (80) 1384 (86) <0.001 
   Coronary angiogram 831 (17) 100 (9.5) 164 (15) 235 (20) 332 (21) <0.001 
   Carotid ultrasound 885 (18) 146 (14) 180 (16) 256 (22) 303 (19) <0.001 
Data presented as number (percentage) or median [interquartile range]. 
a Chi-square test  for categorical variables and ANOVA for continuous variables (e.g. age, dialysis vintage).  
b
 Income was categorized according to fifths of average neighborhood income, with the first quintile calculated 
as the lowest income and the fifth quintile as the highest income. Missing values (0.3%) were categorized into 
the middle quintile. 
c Urban location indicates a population >10,000. 
d Recipients identified as pre-emptive in the Canadian Organ Replacement Register were assessed for the 
presence of dialysis codes and re-classified as hemodialysis (n=26) or peritoneal dialysis (n=35). 
e Delayed graft function was defined as a dialysis code within the first 7 days of transplantation. 
f Primary non-function was defined as 3 dialysis codes on 3 separate days with at least 1 dialysis 
code appearing in the first 7 days of transplantation, between day 8 and 30 of transplantation, and 
between day 31 and 60 of transplantation. 
g Assessed by the presence of a diagnostic or procedural code in the 3 years prior to the transplant except for 
hypertension and diabetes mellitus which are defined as the presence of either 2 OHIP codes or 1 
hospitalization with a diagnosis of hypertension or diabetes mellitus, respectively, in the 3 years prior to the 
transplant (an algorithm previously validated for hypertension and diabetes mellitus).(46,47) 
Abbreviations: CABG, coronary artery bypass graft; ESRD, end-stage renal disease; OHIP, Ontario Health 
Insurance Plan; PCI, percutaneous coronary intervention; TIA, transient ischemic attack. 
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4.2   Baseline Characteristics: General Population 
The baseline characteristics of the matched general population (n=19,816) are presented 
in Table 3. The total follow-up time for the general population was 58,673 person-years. 
As expected, kidney transplant recipients had more co-morbidities than the general 
population, including coronary artery disease (31% vs. 4.9%), hypertension (74% vs. 




Table 3: Baseline characteristics of the matched general population in Ontario by era. 











Age (years) 49 [38-59] 45 [35-55] 47 [36-57] 51 [41-60] 53 [42-62] <0.001 
Male 12,480 (63) 2656 (63) 2724 (61) 3036 (64) 4064 (63) 0.039 
Income quintileb       
   Lowest 3955 (20) 859 (20) 890 (20) 929 (20) 1277 (20) 
0.82    Middle 3846 (19) 837 (20) 839 (19) 899 (19) 1271 (20) 
   Highest 4139 (21) 835 (20) 920 (21) 1001 (21) 1383 (21) 
Urban residencec 17,444 (88) 3699 (88) 3922 (88) 4128 (87) 5695 (88) 0.41 
Co-morbiditiesd       
   Coronary artery disease 980 (4.9) 180 (4.3) 178 (4.0) 258 (5.5) 364 (5.6) <0.001 
   Hypertension 3981 (20) 611 (15) 750 (17) 1038 (22) 1582 (25) <0.001 
   Diabetes mellitus 1608 (8.1) 216 (5.2) 268 (6.0) 407 (8.6) 717 (11) <0.001 
   Myocardial infarction 118 (0.6) 21 (0.5) 29 (0.7) 26 (0.5) 42 (0.7) 0.71 
   PCI 87 (0.4) 7 (0.2) 10 (0.2) 24 (0.5) 46 (0.7) <0.001 
   CABG surgery 72 (0.4) 12 (0.3) 16 (0.4) 17 (0.4) 27 (0.4) 0.75 
   Heart failure 225 (1.1) 45 (1.1) 52 (1.2) 48 (1.0) 80 (1.2) 0.70 
   Stroke/TIA 57 (0.3) 14 (0.3) 9 (0.2) 15 (0.3) 19 (0.3) 0.66 
Cardiovascular investigationsd       
   Holter monitor 610 (3.1) 106 (2.5) 96 (2.2) 149 (3.2) 259 (4.0) <0.001 
   Echocardiography 1542 (7.8) 208 (5.0) 256 (5.8) 376 (8.0) 702 (11) <0.001 
   Stress test 1675 (8.5) 246 (5.9) 294 (6.6) 438 (9.3) 697 (11) <0.001 
   Coronary angiogram 264 (1.3) 37 (0.9) 42 (0.9) 68 (1.4) 117 (1.8) <0.001 
   Carotid ultrasound 426 (2.1) 67 (1.6) 68 (1.5) 117 (2.5) 174 (2.7) <0.001 
Data presented as number (percentage) or median [interquartile range]. 
a Chi-square test for categorical variables and ANOVA for continuous variables (e.g. age).  
b
 Income was categorized according to fifths of average neighborhood income, with the first quintile calculated 
as the lowest income and the fifth quintile as the highest income.  
c Urban location indicates a population >10,000.  
d Assessed by the presence of a diagnostic or procedural code in the 3 years prior to the transplant except for 
hypertension and diabetes mellitus which are defined as the presence of either 2 OHIP codes or 1 
hospitalization with a diagnosis of hypertension or diabetes mellitus, respectively, in the 3 years prior to the 
transplant (an algorithm previously validated for hypertension and diabetes mellitus).(46,47) 




4.3   Primary Outcome: Death or Major Cardiovascular Event 
Kidney Transplant Recipients 
The 3-year cumulative incidence and incidence rate of death or first major cardiovascular 
event for the entire cohort and for each era are presented in Table 4. There were a total of 
445 composite outcome events (263 deaths and 182 major cardiovascular events, of 
which, 81 were myocardial infarctions) within the first 3 years following kidney 
transplantation (9.0%; 95% confidence interval [CI] 8.2% to 9.8%; 3.2 events per 100 
person-years). The 3-year cumulative incidence of death or major cardiovascular event 
remained stable from 8.4% in 1994-1997 to 9.0% in 2006-2009 (p=0.41). When we 
adjusted for age, sex, and a history of coronary artery disease, myocardial infarction, 
hypertension, and diabetes mellitus, the risk of death or major cardiovascular event 
steadily declined across the eras (2006-2009 adjusted hazard ratio, aHR, 0.70; 95% CI 
0.54 to 0.92; p=0.009; referent 1994-1997). 
As expected, the highest incidence rate for each era was in the first 0-3 months 
after transplantation and steadily declined thereafter (Table 5). Overall, the incidence rate 
was 7.96 events per 100 person-years for the first 0-3 months following transplantation, 
2.18 in the 4-12 months following transplantation, and 1.75 in the 13-36 months 
following transplantation. Among recipients who experienced an event, the time from 
transplantation to death or major cardiovascular event remained stable throughout the 
eras with a median time to event of 0.7 years (IQR 0.2 to 2.0) in 1994-1997 and 1.3 years 





















Number (%) of events 445 (9.0) 88 (8.4) 94 (8.5) 117 (9.9) 146 (9.0) 0.41 
Number of events  
per 100 person-years 
3.2 2.9 3.0 3.5 3.2  













Number (%) of types of eventsc       
   Death 263 (5.3) 51 (4.9) 49 (4.4) 79 (6.7) 84 (5.2) 0.33 
   Myocardial infarction 81 (1.6) 18 (1.7) 21 (1.9) 17 (1.4) 25 (1.5) 0.56 
   PCI or CABG surgeryd 68 (1.4) 13 (1.2) 16 (1.4) 10 (0.8) 29 (1.8) 0.34 
   Ischemic stroke 33 (0.7) 6 (0.6) 8 (0.7) 11 (0.9) 8 (0.5) 0.83 




















a Major cardiovascular event was defined as either myocardial infarction, PCI, CABG surgery, or ischemic 
stroke. 
b Cochran-Armitage test for trend except for hazard ratios for which Chi square was used..  
c Only the first event is considered in this analysis. 
d Due to the low number of events and for privacy reasons, the outcomes for PCI and CABG are reported in 
combination in this table. 
e Adjusted for age, sex, and a history of coronary artery disease, myocardial infarction, hypertension, and diabetes 
mellitus at the time of transplantation.  
Abbreviations: CABG, coronary artery bypass graft; CI, confidence interval; IQR, interquartile range; PCI, 















Table 5: Incidence rate of death or major cardiovascular eventa during 3 follow-up periods after 
kidney transplantation for recipients in each era. 
Era Incidence rate per 100 person-years (95% confidence interval)b 
 0-3 months 4-12 months 13-36 months 
1994-1997 (n=1048) 8.60 (5.66 to 13.06) 2.67 (1.83 to 3.89) 1.32 (0.96 to 1.80) 
1998-2001 (n=1110) 7.39 (4.77 to 11.46) 1.76 (1.12 to 2.75) 1.74 (1.34 to 2.27) 
2002-2005 (n=1182) 6.59 (4.20 to 10.33) 2.43 (1.68 to 3.52) 2.10 (1.66 to 2.65) 
2006-2009 (n=1614) 8.67 (6.20 to 12.14) 1.79 (1.23 to 2.59) 1.84 (1.48 to 2.27) 
Overall  7.96 (6.53 to 9.70) 2.18 (1.80 to 2.63) 1.75 (1.55 to 1.99) 
a Major cardiovascular event was defined as either myocardial infarction, PCI, CABG surgery, or 
ischemic stroke. 
b Unadjusted Poisson model.  




There was no difference in the primary outcome across the eras within age, sex, or donor 
type strata (Figure 2, Figure 3, and Figure 4, respectively). Throughout the study period, 
as expected a higher proportion of events were observed in the older population (19% for 
recipients ≥65 years old at the time of transplant vs. 7.6% for recipients <65 years; 
p<0.001), in males vs. females (9.6% vs. 7.9%; p=0.04), and in recipients of deceased 
donor kidneys vs. living donor kidneys (11% vs. 5.5%; p<0.001).  
 
Figure 2: 3-year cumulative incidence of death or major cardiovascular event from 1994 
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Figure 3: 3-year cumulative incidence of death or major cardiovascular event from 1994 




Figure 4: 3-year cumulative incidence of death or major cardiovascular event from 1994 



















































































Comparison to the General Population 
A comparison of the primary outcome in kidney transplant recipients to the general 
population (matched on age, sex, and index date) is presented in Figure 5. Overall, the 3-
year cumulative incidence and rate of death or first major cardiovascular event was lower 
in the general population (2.6%; 95% CI 2.4% to 2.9%; 0.89 events per 100 person-years; 
p<0.001) compared to recipients, with a trend towards increasing incidence over time 
(2.0% in 1994-1997 to 2.8% in 2006-2009; p=0.008).  
Figure 5: 3-year cumulative incidence of death or major cardiovascular event from 1994 
to 2009 in matched kidney transplant recipients and general population. The general 
population cohort excluded individuals with chronic kidney disease, a history of dialysis 
or previous kidney transplantation. Kidney transplant recipients were matched 1:4 to 






































4.4   Additional Outcome: Death  
The components of the primary outcome were examined separately. There were 306 
deaths within 3 years following transplantation (6.2%; 95% CI 5.5% to 6.9%; 2.1 events 
per 100 person-years) with no difference across the eras (5.6% in 1994-1997 vs. 6.3% in 
2006-2009; p=0.17) (Table 6). The 3-year cumulative incidence and rate of death was 
lower in the general population (1.4%; 95% CI 1.3% to 1.6%; 0.5 events per 100 person-
years; p<0.001) compared to recipients, with a trend towards increasing incidence over 
time (p=0.017) (Figure 6). 
 
Table 6: Secondary outcomes of 3-year cumulative incidence of death, cardiovascular events, and 
cardiovascular investigations among kidney transplant recipients. 













Death 306 (6.2) 59 (5.6) 56 (5.0) 89 (7.5) 102 (6.3) 0.17 
Cardiovascular events  
(censored for death)b       
   Major cardiovascular eventc 182 (3.7) 37 (3.5) 45 (4.1) 38 (3.2) 62 (3.8) 0.92 
   Myocardial infarction 81 (1.6) 18 (1.7) 21 (1.9) 17 (1.4) 25 (1.5) 0.56 
   PCI  67 (1.4) 12 (1.1) 15 (1.4) 11 (0.9) 29 (1.8) 0.21 
   Ischemic stroke 36 (0.7) 8 (0.8) 8 (0.7) 11 (0.9) 9 (0.6) 0.61 
Cardiovascular investigations       
   Holter monitor 395 (8.0) 64 (6.1) 82 (7.4) 80 (6.8) 169 (11) <0.001 
   Echocardiography 1898 (38) 305 (29) 359 (32) 450 (38) 784 (49) <0.001 
   Stress test 1133 (23) 204 (19) 222 (20) 269 (23) 438 (27) <0.001 
   Coronary angiogram 81 (1.6) 10 (1.0) 17 (1.5) 16 (1.4) 38 (2.4) 0.008 
   Carotid ultrasound 366 (7.4) 74 (7.1) 84 (7.6) 73 (6.2) 135 (8.4) 0.32 
a Cochran-Armitage test for trend. 
b Due to the low number of events and for privacy reasons, the outcomes for CABG are not reported in this 
table. The total number of events was 42 (0.8%) with no significant change over time (p=0.63). 
c Major cardiovascular event was defined as either myocardial infarction, PCI, CABG surgery, or ischemic 
stroke. 
Abbreviations: CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention. 
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Figure 6: 3-year cumulative incidence of death from 1994 to 2009 in matched kidney 
transplant recipients and general population. The general population cohort excluded 
individuals with chronic kidney disease, a history of dialysis or previous kidney 
transplantation. Kidney transplant recipients were matched 1:4 to members of the general 
























4.5   Additional Outcome: Death-Censored Major 
Cardiovascular Events 
In kidney transplant recipients, there was no significant change in the 3-year cumulative 
incidence of death-censored major cardiovascular events (182 events; 3.7%; 95% CI 
3.2% to 4.2%; 1.2 events per 100 person-years) across the eras (3.5% in 1994-1997 vs. 
3.8% in 2006-2009; p=0.92) (Table 6). The 3-year incidence of death-censored major 
cardiovascular event was lower in the general population (1.3%; 95% CI 1.2% to 1.5%; 
0.4 events per 100 person-years; p<0.001) compared to recipients, with no significant 
change over time in either group (p=0.14) (Figure 7).  
In kidney transplant recipients, the 3-year cumulative incidence of myocardial 
infarction was 1.7% in 1994-1997 compared to 1.5% in 2006-2009 (p=0.56) (Table 6). 
When examined separately, the 3-year cumulative incidences of percutaneous coronary 
intervention, coronary artery bypass graft surgery, and ischemic stroke also remained 
stable throughout the eras.  
There was a trend towards more cardiac investigations (Holter monitor, 
echocardiography, stress testing, coronary angiogram) in the 3-years following kidney 
transplantation in the more recent eras (Table 6). The use of carotid ultrasounds remained 
stable throughout the eras. 
Lastly, in the post-operative transplant period, the 30-day cumulative incidence of 
myocardial infarction was 1.5% while the 30-day cumulative incidence of ischemic 




Figure 7: 3-year cumulative incidence of death-censored major cardiovascular event 
from 1994 to 2009 in matched kidney transplant recipients and general population. The 
general population cohort excluded individuals with chronic kidney disease, a history of 
dialysis or previous kidney transplantation. Kidney transplant recipients were matched 



































Chapter 5 : Discussion 
 
5.1   Summary of Key Findings  
In this study, we found that the 3-year cumulative incidence of death or major 
cardiovascular event in kidney transplant recipients was 9.0% and, reassuringly, has 
remained stable over time despite increasing recipient age and co-morbidities in the more 
recent eras. When we adjusted for age, sex, and baseline co-morbidities, there was a trend 
towards a decreasing risk of death or major cardiovascular event across the eras. 
The incidence rate was highest in the first 3 months after transplantation and steadily 
declined thereafter. There was no difference in the primary outcome when the results 
were stratified by age, sex, and donor type. Compared to the general population, kidney 
transplant recipients have a higher incidence of death or major cardiovascular event.  
Similar results were seen when the components of the primary outcome were 
examined separately. The 3-year cumulative incidence of death in kidney transplant 
recipients was 6.2% and for death-censored major cardiovascular event was 3.7%, with 
no significant change over time for either outcome. The 3-year cumulative incidence of 
myocardial infarction was 1.6% and for ischemic stroke was 0.7% with no significant 
change over time.  
 
5.2   Comparison of Results to Previous Research 
Similar to an Australian study, we found a trend towards a greater proportion of older 
recipients with more co-morbidities in recent years.(8) This trend may be due to the 
increasing rate of treated end-stage renal disease (ESRD) among the elderly (over a third 
are now >70 years old).(48,49) While younger recipients do have higher patient and graft 
survival rates compared to older recipients,(49) studies have shown that older patients 
still have a survival benefit with kidney transplantation compared to remaining on 
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dialysis and that death-censored graft survival is similar to younger recipients.(1,50–53) 
This raises ethical dilemmas in the allocation of scarce resources and a growing number 
of patients on the transplant waiting list.(54,55) Of note, the United States (U.S.) recently 
implemented a revised deceased donor allocation policy in December 2014 which 
prioritizes kidney transplant candidates with the highest expected post-transplant survival 
(a metric based on age, diabetes mellitus, dialysis time, and prior transplant status) for the 
highest quality organs.(56) Despite the favourable outcomes with transplantation for 
older patients on the waiting list, there are concerns regarding this population’s higher 
risk of death with a functioning graft as well as post-transplant complications including 
cardiovascular events.(54) Reassuringly, we found that the 3-year cumulative incidence 
of death or major cardiovascular event in this older age group has remained stable. 
The overall 3-year cumulative incidence of death or major cardiovascular event 
was 9.0% in our cohort while the 3-year cumulative incidence of myocardial infarction 
and ischemic stroke were 1.6% and 0.7%, respectively. These estimates are lower than 
the 11% and 3.5% 3-year cumulative incidence of myocardial infarction and ischemic 
stroke reported in Lentine’s et al. retrospective studies of Medicare-insured kidney 
transplant recipients followed through the United States Renal Data System 
(USRDS).(7,57) The higher cumulative incidence of myocardial infarction in the U.S. 
study compared to our Canadian study may be due to differences in baseline 
characteristics between the two cohorts and/or how myocardial infarction events were 
captured. The U.S. cohort had a higher proportion of older recipients (22% of U.S. 
recipients were ≥60 years compared to 12% of our recipients were ≥65 years) and a 
higher proportion of recipients for whom diabetes mellitus was the primary cause of 
ESRD (25% vs. 18%). The U.S. cohort also had a higher proportion of recipients with 
concurrent co-morbidities at the time of transplant. For example, 45% of U.S. recipients 
had diabetes mellitus vs. 26% of our recipients and 8% of U.S. recipients had a history of 
myocardial infarction pre-transplant compared to 2% of our cohort. However, baseline 
co-morbidities may be under-represented in our cohort given that they only reflect 
recorded diagnostic and procedural codes present in the 3 years prior to transplantation. 
In addition, we restricted our events to hospitalizations within 3 years of transplantation 
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where the most responsible diagnosis was myocardial infarction whereas the U.S. study 
included any Medicare billing claims within 3 years of transplantation with a diagnosis of 
myocardial infarction or death due to myocardial infarction. A previous validation study 
has shown that a most responsible diagnosis of acute myocardial infarction has a 
specificity, sensitivity, and positive predictive value of 93%, 89%, and 89%, respectively. 
Thus, myocardial infarctions or strokes occurring in the immediate peri-operative period 
are unlikely to be captured in our primary analysis, as the most responsible diagnosis 
related to the admission would likely be the kidney transplantation rather than 
complications arising post-operatively.  
Regarding peri-operative events, in our secondary analysis we did not limit the 
hospital diagnostic code to most responsible or primary diagnosis and found that the 30-
day cumulative incidence of myocardial infarction was 1.5% while the 30-day cumulative 
incidence of ischemic stroke was 0.3%. This is similar to a previous retrospective single-
center study by Humar et al. who found that in a cohort of 2694 kidney transplant 
recipients the 30-day incidence of myocardial infarction was 1.6%.(58) We did confirm 
that the highest incidence rate of death or major cardiovascular event occurred during the 
first 0-3 months after transplantation (7.96 events per 100 person-years in the first 0-3 
months vs. 2.18 events per 100 person-years in the 4-12 months vs. 1.75 events per 100 







5.3   Further Discussion of Results  
There are many possible reasons for the stable rate of observed events in our cohort 
despite the changing baseline characteristics of our recipients. One reason may be the 
increase in living donor kidneys over time for which these recipients, in our study, were 
found to have a lower risk of death or cardiovascular event compared to deceased donor 
kidney recipients (overall, 5.5% for living donor kidneys vs. 11% for deceased donor 
kidneys). Another possible reason may be the careful assessment and selection process of 
kidney transplant candidates. In recent years, we noted a dramatic increase in the 
proportion of recipients who received cardiac investigations in the 3 years prior to their 
transplant, likely as part of their transplant assessment and/or cardiac surveillance while 
on the transplant waiting list. A survey of transplant programs in the U.S. showed wide 
variability in the use of invasive and non-invasive cardiac investigations used as part of 
the screening and surveillance of potential kidney transplant candidates.(59) Among 
Medicare-insured transplant recipients in the U.S. between 1991 and 2004, 46% (65% of 
high-risk and 20% of lower-risk patients) underwent cardiac evaluation testing before 
transplantation.(60) Kidney transplant recipients who were younger, female, African-
American, or had a shorter duration on dialysis were less likely to undergo pre-transplant 
cardiac evaluation with non-invasive stress testing and angiography. 
Although there are recommendations on the cardiac evaluation and surveillance of 
potential transplant recipients, these tests have been inconsistent in predicting or 
mitigating post-transplant cardiovascular mortality or morbidity.(6) A Cochrane review 
of cardiac testing for coronary artery disease in kidney transplant candidates suggested 
that dobutamine stress echocardiography is the screening investigation of choice but 
recognized the limitation of cardiac testing in predicting cardiac event-free survival after 
transplantation.(61) Similarly, a Canadian prospective study from British Columbia of 
604 patients on the kidney transplant waiting list between 1998 and 2001 found that the 
use of non-invasive cardiac investigation prior to transplant was not predictive of the time 
to a cardiovascular event post-transplant.(62) In our study, we cannot attribute the 
stability of post-transplantation cardiovascular events to the increase in cardiac testing 
pre-transplantation. Currently there is no evidence from randomized trials demonstrating 
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that pre-operative cardiac screening of asymptomatic patients reduces risk of major 
cardiovascular events or improves survival after transplantation or other forms of 
surgery.(6)  
Finally, progressive improvements in the diagnosis and medical management of 
cardiovascular events in patients with chronic kidney disease (CKD) may explain our 
findings.(29,63–65) As above, there is a lack of randomized controlled trials proving 
efficacy of pharmacological interventions in the reduction of cardiovascular events in 
patients with renal disease as these patients are often excluded from the trials.(66) Thus, 
physicians often extrapolate findings from the general population to the CKD population 
despite their unique cardiac risk factors and pathophysiology.(29) Unfortunately, we did 
not have complete information on cardio-protective medications, such as beta-blockers or 
statins, in our data sources given that a significant proportion of recipients are covered by 
private drug plans.  
Despite the stable cumulative incidence of cardiovascular events over time, 
kidney transplant recipients had a 6.4% higher risk of death or major cardiovascular event 
compared to the general population. As previously stated, this is likely due to the 
combination of traditional cardiovascular risk factors and renal-specific cardiovascular 
risk factors that are highly prevalent in this unique patient population.(21,23) Traditional 
cardiovascular risk factors include hypertension, diabetes mellitus, hyperlipidemia, 
smoking, older age, and physical inactivity. Renal-specific factors include decreased 
renal function (compared to the general population), immunosuppressive medications, 
episodes of rejection and graft loss, and donor type (living vs. deceased 
donors).(20,23,24) In our subgroup analyses, the risk of death or major cardiovascular 
event was higher in kidney transplant recipients who were older and had received kidneys 




5.4   Study Strengths  
Our study has a number of strengths. To our knowledge, this is the first study assessing 
secular trends of death and major cardiovascular events in kidney transplant recipients. 
Our study was made possible because of Ontario’s universal healthcare benefits, with the 
collection of all healthcare encounters for all citizens, including almost 5000 transplant 
recipients followed in this study. This minimizes concerns about selection and 
information biases. We relied on diagnostic and procedural codes for our outcomes with 
proven validity compared to chart review. 
 
5.5   Study Limitations 
There are some limitations to our study. We did not have accurate and complete data to 
compare our results to a population of patients receiving chronic dialysis while on the 
transplant waiting list. Cause of death could not be accurately obtained in our data 
sources. We relied on administrative data collected for non-research purposes, which 
limit the type of data available for applying inclusion/exclusion criteria as well as for 
outcome measurements. Claims are surrogate measures for diagnoses and procedures, but 
have been shown to have high sensitivity and specificity compared with chart review and 
registry data in the general Ontario population (Appendix 3). High sensitivity of 
Medicare billing claims for cardiovascular diagnoses and procedures in the kidney 
transplant population has also been demonstrated in the U.S.(67) Residual confounding, 
inherent to any observational study, may affect the association between year of transplant 
and outcomes. Historical information such as smoking, cardio-protective medications, 
immunosuppression use, physical exam values such as blood pressure measurements, 
laboratory data such as serum creatinine or cardiac troponin, and investigational findings 
such as echocardiography results were unavailable or incomplete from our data sources. 
Lastly, secular changes in coding practices or outcome definitions may have influenced 




5.6   Conclusion 
We report a stable cumulative incidence over time of post-transplant death or major 
cardiovascular event in kidney transplant recipients despite increasing recipient age and 
co-morbidities. Our results are reassuring for transplant programs and may reflect 
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Appendix 1: Data creation plan. 
Secular Trends in Cardiovascular Disease Among Kidney Transplant Recipients 
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Research Program Kidney, Dialysis, & Transplantation (KDT) 
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Ngan N. Lam  
Amit X. Garg  
S. Joseph Kim  
Greg A. Knoll 
Salimah Z. Shariff  
Kyla L. Naylor  
Eric McArthur  
Alvin H. Li  
Responsible for Updates Ngan Lam 
PIA Approved? Yes (April 15, 2013) 
DCP update history 
Version 11: February 5, 2015 (NL, after receiving co-author comments) 
Version 10: November 3, 2014 (NL, after drafting manuscript) 
Version 9: July 6, 2014 (NL, after updating variable library) 
Version 8: May 4, 2014 (NL, after reviewing DCP again) 
Version 7: December 28, 2013 (NL, after receiving results) 
Version 6: June 13, 2013 (NL, after receiving Table 1) 
Version 5: June 3, 2013 (NL, after call with JK/GK and meeting with EM/SD) 
Version 4: May 15, 2013 (NL, after meeting with entire group) 
Version 3: May 3, 2013 (NL, after emailing group, meeting with SM and KN) 
Version 2: April 14, 2013 (NL, after meeting with JF and SD) 
Version 1: March 29, 2013 (NL, after meeting with AG) 
Version 0: March 12, 2013 (NL) 
Short Description of 
Research Question 
Our aim is to assess whether rates and outcomes of major adverse 
cardiovascular events (MACE) in kidney transplant recipients have changed over 
time in Ontario, Canada from 1994 to 2009. Specifically, we will assess incidence 
and temporal (annual) trends of major adverse cardiovascular events after kidney 
transplantation. We will compare these incidences to the general population. 
List of Datasets Used 
1. CORR (Jan 1981 – Dec 2012) 
2. RPDB (Jan 1991 – Dec 2012) 




 Acute care (insttype = ‘AP’ or ‘AT’) 
Diagnosis Type (dxtype) 
 All (alldx) (for baseline characteristics) 
 Most responsible diagnosis (M) (for cardiovascular outcomes) 
Study period 
 Prior to 2002 fiscal year à INCLUDE ICD-9 CODES in Appendix A, B, E 
 From 2002 fiscal year and onwards à INCLUDE ICD-10 CODES in Appendix 
A, B, E 





 Do include index date in look-forward period (start at index) 
Include abandoned procedures? 
 No 
4. OHIP (July 1991 – Dec 2012) 
Claim Type 
 Non-lab claims 
Code Types 
 Feecodes à INCLUDE FEECODES in Appendix A, B, E 
 Diagnosis codes à INCLUDE DIAGNOSIS CODES in Appendix A, B, E 
Design: Retrospective Cohort Study 
Defining the Cohort 
Index Event Year of first kidney-only transplantation (from a deceased or living donor) during the study 

















1) Cohort A: Kidney transplant recipients (KTx) 
All incident kidney-only transplant recipients in Ontario from January 1, 1994 to December 
31, 2009 with a valid IKN.  
CORR Dataset: RECIPIENT_TREATMENT 
- Variable:  TREATMENT_CODE = 171 (Acute Care Hospital, Transplantation, Total Care) 
- Variable: TREATMENT_DATE (date of transplant) 
- Variable: TRANSPLANTED_ORGAN_TYPE_CODE[1-3] 
 
CORR: TRANSPLANTED_ORGAN_TYPE_CODE[1-3] Code 
Kidneys/Dialysis (includes enbloc transplants) 10 
Kidney – Left 11 
Kidney – Right 12 
Kidney – One (from conversion) 18 
Kidney – Two (from conversion) 19 
 
2) Cohort B: General population (GP)  
Restrict to those in RPDB. Randomly assign an index date (from January 1, 1994 to 
December 31, 2009) to all based on the distribution of the index dates in the kidney 
transplant recipients above (minimum, maximum, 25th, 50th, 75th percentiles). 
Exclusions 
(In order)  
(Table 1) 
Data cleaning steps (both cohorts) 
1. Exclude if invalid or missing IKN, date of birth, or sex  
2. Death before the index date in RPDB  
3. Exclude non-Ontario residents (use the “%getdemo” macro, the “prcddablk” variable, 
exclude recipients whose province code, pr, is not “35”) 
 
Further exclusions (4 to 5a-c are both cohorts) 
4. Exclude if age <18 at index date (RPDB)  
5. Look back from the index date to 1981 for CORR or 1991 for CIHI-DAD/OHIP for the 
following: 
a. Exclude if repeat/previous kidney transplant or history of non-kidney transplant.  
CORR Dataset: RECIPIENT_TREATMENT 
- Variable: TREATMENT_CODE = 171 or 181 
For Cohort A (KTx), only include first transplant event, not re-transplants; i.e. first 171 for a 
given patient. Index transplant should be the first transplant only. 
b. Exclude if CORR reports graft number ≥2  
CORR Dataset: TRANSPLANTED_KIDNEY 
- Variable: GRAFT_NUM ≥2  
For Cohort A (KTx), should be 1 for all recipients. 
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c. Exclude if evidence of CIHI-DAD or OHIP codes for kidney transplant (Appendix A) from 
beginning of available databases to -60 days before index date 
 
Cohort A (KTx) only 
6. Exclude if simultaneous multi-organ transplant recipient including kidney-pancreas 
CORR Dataset: RECIPIENT_TREATMENT 
- Variable: TRANSPLANTED_ORGAN_TYPE_CODE[1-3] as above (in inclusion #1) 
 
Cohort B (GP) only 
6. Look back from the index date to 1981 for CORR or 1991 for CIHI-DAD/OHIP for the 
following: 
a) Exclude if evidence of chronic dialysis in CORR. 
CORR Dataset: RECIPIENT_TREATMENT (Dialysis codes in Appendix D) 
b) Exclude if evidence of CIHI-DAD or OHIP codes for dialysis (Appendix A) before the 
index date 
7. Exclude if evidence of CIHI-DAD code for CKD before the index date (look back to 1991) 
(CKD codes in Appendix D). 
Matching Match up to 4 controls (Cohort B [GP]) to each recipient (Cohort A [KTx]) on the following 
characteristics: 
i) Index date (± 6 months; when possible, ensure control has the same index year as the 
recipient) 
ii) Age at index date (± 1 year) 
iii) Sex 
Size of Cohort Based on previous analyses, we anticipate that between 1994 to 2009, there will be 
approximately 5000 incident kidney-only transplant recipients (from living or deceased 
donors) eligible for inclusion into the study cohort. 
Time Frame Definitions 
 
Accrual Start/End Dates Start: January 1, 1994 
End: December 31, 2009 
Max Follow-up Date December 31, 2012 
When Does Observation 
Window Terminate? 
 
Termination occurs (whichever comes first): 
1. Observed outcome/event (see Outcome Definitions section) 
2. End of follow-up (either pre-defined follow-up period of 30 days, 3 years, 5 
years, or 10 years based on outcome) or end of study period (Dec 31, 2012) 
3. Death 
Look-back Window(s) 3 years prior to index date for co-morbid conditions (earliest potential date is 
January 1, 1991) 
 
 
Look-back Window Observation Window 
(in which to look for outcomes) 
Cohort Entry Date 





or Risk Factor 
Year of kidney-only transplantation from either a living or deceased donor.  
CORR Dataset: RECIPIENT_TREATMENT 




Table 2b,  
Table 2c) 
(Appendix B) 
Note: There will be a separate cohort for each accrual era (era that patient is put into 
depends on when the patient has their transplant: 1994-1997, 1998-2001, 2002-2005, 2006-
2009). Therefore, there will be 4 consecutive cohorts for the primary outcome.  
 
Observed at the time of the index date – Demographics (CORR, RPDB) (Table 2): 
 
Record mean (with standard deviation), median (with interquartile range), minimum, 
maximum, and/or categorical number N(%) for the following variables as indicated for all 3 
cohorts except where indicated: 
 
1. Age at index date: Years, mean±SD, median (IQR), minimum, maximum; Categories: ≤44 
years, 45-64 years, ≥65 years, N(%) (RPDB) 
2. Sex: Female, Male, N(%) (RPDB) 
3. Race (Cohort A [KTx] only): Categories: Caucasian (White), Asian, Black, Indian 
Subcontinent, Other, Unknown/Missing, N(%) 
CORR Dataset: RECIPIENT 
- Variable: RACIAL_ORIGIN_CODE  




Caucasian (White) French Canadians, European, Australian, Russian 
ancestry 
01 
Asian Chinese, Japanese, Vietnamese, Korean, 
Taiwanese 
02 
Black African, Jamaican, Haitian, Somali 03 
Indian Subcontinent Indian, Pakistani, Bangladesh 05 
Other Filipino 
Aboriginal (North American Indian, Metis, Inuit) 
Middle Eastern/Arabian (Saudi Arabian, Iranian, 
Iraqi, Jordanian, Syrian, Armenian, Algerian) 










Unknown Unknown 98 
 
4. Income quintile: Quintile 1-5, Missing, N(%) (PCCF, use PSTLYEAR data and index year)  
5. Rural location: Rural, Urban, Missing, N(%) 
 
Observed at the time of the index date – Kidney-related factors (CORR) (Table 2): 
 
Record categorical number (%) for the following variables (Cohort A [KTx] only): 
 
1. Index date: N(%); Categories/Eras: 1994-1997, 1998-2001, 2002-2005, 2006-2009  
CORR Dataset: RECIPIENT_TREATMENT 
- Variable: TREATMENT_CODE = 171  
- Variable: TREATMENT_DATE 
- Variable: TRANSPLANTED_ORGAN_TYPE_CODE[1-3] (see table in Inclusion Criteria) 
 
2. Primary cause of end-stage renal disease: Glomerulonephritis/Autoimmune, Cystic Kidney 
Disease, Diabetes, Renal Vascular Disease, Other, Unknown/Missing, N(%) (Appendix C) 
CORR Dataset: RECIPIENT_TREATMENT 
52 
 
- Variable: PRIMARY_DIAGNOSIS_KIDNEY 
Look back to the beginning of CORR (1981) to find primary cause of ESRD. 
 
3. Dialysis modality: Hemodialysis, Peritoneal Dialysis, Other, Pre-emptive/Missing, N(%) 
(Appendix D) 
CORR Dataset: RECIPIENT_TREATMENT 
- Variable: TREATMENT_CODE 
Note: For patients with Missing dialysis modality (assumed to be pre-emptive recipients), look 
back for evidence of chronic dialysis codes and re-classify these patients as HD or PD (see 
codes in Appendix B). For duplicate codes (G333, H540, H740), classify as HD. 
 
4. Donor type: Living, Deceased, Unknown/Missing, N(%) 
CORR Dataset: TRANSPLANTED_KIDNEY 
- Variable: DONOR_TYPE_CODE 
 
 
Observed in the first 60 days of the index date – Kidney-related factors (CIHI-DAD, 
OHIP) (Table 2): 
 
Record categorical number (%) for the following variables (Cohort A [KTx] only): 
 
1. Delayed graft function: At least one code for dialysis appearing in the first 7 days after the 
index date (see Appendix B for dialysis codes), N(%) 
 
2. Primary renal allograft non-function: At least three codes for dialysis on three different days 
with at least one code appearing in the first 7 days after the index date, in the 8-30 days after 
the index date, and in the 31-60 days after the index date (see Appendix B for dialysis 
codes), N(%) 
 
Look back 3 years from index date (CIHI-DAD, OHIP) (Table 2): 
 
CIHI-DAD 
Diagnosis Type (dxtype) 
 All (alldx) 
 




1. Coronary artery disease (CAD) without angina (CIHI-DAD, OHIP) 
2. Myocardial infarction (CIHI-DAD) 
3. Percutaneous coronary intervention (PCI) (CIHI-DAD, OHIP) 
4. Coronary artery bypass graft (CABG) surgery (CIHI-DAD, OHIP) 



















Deceased Deceased donor 01 
Unknown Unknown/Out-of-country transplant 98 
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5. Heart failure (CIHI-DAD, OHIP) 
6. Hypertension (CIHI-DAD, OHIP): Define as evidence of two OHIP claims for hypertension 
OR one hospitalization with a diagnosis of hypertension within the three-year look-back 
window 
7. Diabetes (CIHI-DAD, OHIP): Define as evidence of two OHIP claims for diabetes OR one 
hospitalization with a diagnosis of diabetes within the three-year look-back window 
8. Stroke/TIA (CIHI-DAD) 
 
Cardiac testing (a recipient can have ≥1 test/visit in the 3-year look-back window): 
1. Carotid ultrasound (CIHI-DAD, OHIP) 
2. Coronary angiogram (CIHI-DAD, OHIP) 
3. Echocardiography (CIHI-DAD, OHIP) 
4. Holter monitoring (CIHI-DAD, OHIP) 
5. Stress test (CIHI-DAD, OHIP) 
 
Variable look-back window (CORR) (Table 2): 
 
Record mean (with standard deviation), median (with interquartile range), minimum, 
maximum, and/or categorical number (%) for the following variables as indicated (Cohort A 
[KTx] only): 
 
1. Time on dialysis prior to transplantation date: Years, mean±SD, median (IQR), minimum, 
maximum. 
CORR Dataset: RECIPIENT_TREATMENT 
- Variable: TREATMENT_DATE ≠171 for first date 
- If 171 is the first date, then assume pre-emptive transplant (i.e. Years on dialysis = 0) 
- Calculation: Time on dialysis (years) = ([Treatment_Date] & [Treatment_Code] “171”) – 














 Acute care (insttype = ‘AP’ or ‘AT’) 
Diagnosis Type (dxtype) 
 Most responsible diagnosis (M) 
 All (alldx) (for 30-day outcomes) 
Study period 
 Prior to 2002 fiscal year à INCLUDE ICD-9 CODES in Appendix E 
 From 2002 fiscal year and onwards à INCLUDE ICD-10 CODES in Appendix E 
Include suspected/questionable diagnoses? 
 No 
Reference date 
 Do include index date in look-forward period (start at index) 
Include abandoned procedures? 
 No 
 
OHIP (July 1991 – Dec 2012) 
Claim Type 
 Non-lab claims 
Code Types 
 Feecodes à INCLUDE FEECODES in Appendix E 




Primary outcome (CIHI-DAD, OHIP) (Table 3a): 
 
1. Composite of death or first major adverse cardiovascular event (MACE) within 3 years of 
index date (myocardial infarction, percutaneous coronary intervention, coronary artery bypass 
graft surgery, ischemic stroke). Use codes defined in Appendix E 
For each cohort era, report the number of events that occurred in the follow-up period within 
that cohort (i.e. not the number of events that occurred that era. For example, a new kidney-
only transplant recipient receives their transplant in 1995 and enters the 1994-1997 cohort. If 
this patient has a stroke in 1998, then the cardiovascular event is reported in the 3-year 
outcomes of the 1994-1997 cohort.) 
 
Secondary outcomes at 3 years (CIHI-DAD, OHIP) (Table 3b): 
 
1. Death within 3 years of index date 
 
2. First major adverse cardiovascular event within 3 years of index date censored for death 
 
3. Major adverse cardiovascular event by type within 3 years of index date (censor for death): 
Here, the denominator is the total number of recipients in each cohort era 
i) Myocardial infarction 
ii) Percutaneous coronary intervention 
iii) Coronary artery bypass graft surgery 
iv) Ischemic stroke 
 
4. Cardiac testing by type within 3 years of index date: 
i) Carotid ultrasound 
ii) Coronary angiogram 
iii) Echocardiography 
iv) Holter monitoring 
v) Stress test 
 
Secondary outcomes at 30 days (CIHI-DAD, OHIP) (Table 3c): 
CIHI-DAD 
Diagnosis Type (dxtype) 
 All (alldx) 
 
5. 30-day cumulative incidence of myocardial infarction  








See Appendix F for Output Tables. 
 
1) Cohort selection (Table 1a, Table 1b, Table 1c): Apply inclusion and exclusion criteria to select the study 
cohorts. For Cohort B (GP), match to the kidney transplant recipients as described above. Provide the final 
cohort number by year. 
 
2) Baseline characteristics (Table 2a, Table 2b, Table 2c): Provide frequencies and descriptive 
characteristics for baseline characteristics for the cohorts accrued in each era of the study period.  
Report % missing data for each variable, as indicated.  
Report categorical variables as proportions. Report continuous variables as means with standard deviations 
for data that is normally distributed or medians with interquartile ranges for skewed data.  
Compare cohort characteristics, on an era basis, using the Chi-square test.  
 
3) Primary outcome (Table 3a): For each era of the study period, report the number of recipients in that 
cohort era (i.e. got their kidney transplant that year), number of recipients from that cohort era who have 
evidence of either death or first major adverse cardiovascular event during the first 3 years of follow-up 
(myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, ischemic 
stroke), the 95% confidence limits for the incidence rate (Wilson score method), the total person-years of 
follow-up (censoring for the outcome, emigration, or end of follow-up), and the event rate per 100 person-
years of follow-up. Repeat the analysis for matched Cohort B (GP). 
For Cohort A (KTx) only: 
i) Repeat the primary analysis using the exponential equation. 
ii) Report the median [IQR] time to first event in years for each era. 
iii) Breakdown of the type of event within 3 years of index date (death, myocardial infarction, percutaneous 
coronary intervention, coronary artery bypass graft surgery, ischemic stroke). Sum of each type should equal 
the total number of events for each cohort era. Sum of the proportions for each cohort era should be 1. 
iv) Stratify the primary analyses by age (<65 vs. ≥65), sex (female, male), and donor type (living donor, 
deceased donor). Report the number of events, the cumulative incidence, the 95% confidence limits, the total 
person-years of follow-up, and the event rate per 100 person-years of follow-up. 
v) Calculate the incidence rate and 95% confidence limits for each era for the following time periods after 
transplantation using Poisson models: 0-3 months, 4-12 months, 13-36 months. 
 
6) Secondary outcomes at 3 years (Table 3b):  
Report the number of events, the cumulative incidence, the 95% confidence limits, the total person-years of 
follow-up, and the event rate per 100 person-years of follow-up for all 3 cohorts. 
 
a) Death within 3 years of index date 
 
b) First major adverse cardiovascular event within 3 years of index date 
 
For Cohort A (KTx) only:  
c) Major adverse cardiovascular event by type within 3 years of index date: 
Here, the denominator is the total number of recipients in each cohort era 
i) Myocardial infarction 
ii) Percutaneous coronary intervention 
iii) Coronary artery bypass graft surgery 
iv) Ischemic stroke 
 
d) Cardiac testing by type within 3 years of index date: 
i) Carotid ultrasound 
ii) Coronary angiogram 
iii) Echocardiography 
iv) Holter monitoring 
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v) Stress test 
 
Compare the primary outcome, on an annual basis, using the Cochrane-Armitage test for linear trend. Use 
joinpoint regression to identify changes in linear slope. 
 
7) Secondary outcomes at 30 days (Table 3c): To assess perioperative cardiovascular complications, 
report the total number of events, the cumulative incidence, and the 95% confidence limits for Cohort A (KTx) 
only: 
i) Myocardial infarctions within 30 days of the index date 






Table 1a: Cohort Selection of Kidney Transplant Recipients 
Table 1b: Cohort Selection of General Population 
Table 1c: Cohort Selection of Chronic Kidney Disease Patients 
Table 2a: Baseline Characteristics of Kidney Transplant Recipients by Era 
Table 2b: Baseline Characteristics of General Population by Era 
Table 2c: Baseline Characteristics of Chronic Kidney Disease Patients by Era 
Table 3a: Primary Outcome at 3 Years 
Table 3b: Secondary Outcomes at 3 Years 
Table 3c: Secondary Outcomes Short and Long-term 
 
Appendices: 
Appendix A: Exclusion Codes 
Appendix B: Baseline Characteristics Codes 
Appendix C: CORR Codes for Primary Cause of End-Stage Renal Disease  
Appendix D: CORR Codes for Treatment Codes for Dialysis 
Appendix E: Diagnostic Codes for Outcome Variables 




Appendix A: Exclusion Codes 
 
Exclusion Variable Databases Codes 
Non-Ontario resident PRCDDABLK (using %getdemo)a  PR ≠ 35 




 Acute care (insttype = ‘AP’ or ‘AT’) 













 Acute care (insttype = ‘AP’ or ‘AT’) 













 Acute care (insttype = ‘AP’ or ‘AT’) 

























Age RPDB  
Sex RPDB   
Race CORR Dataset: RECIPIENT 
- Variable: RACIAL_ORIGIN_CODE  
 
Income quintile PSTLYEAR (using %getdemo)  




Date of transplant CORR Dataset: RECIPIENT_TREATMENT 
- Variable: TREATMENT_CODE = 171  
- Variable: TREATMENT_DATE 
- Variable: TRANSPLANTED_ORGAN_TYPE_CODE[1-3] 
 
Cause of end-stage 
renal disease 
CORR Dataset: RECIPIENT_TREATMENT 
- Variable: PRIMARY_DIAGNOSIS_KIDNEY  
See Appendix C 
Donor type CORR Dataset: TRANSPLANTED_KIDNEY 
- Variable: DONOR_TYPE_CODE 
 
Dialysis modality CORR Dataset: RECIPIENT_TREATMENT 
- Variable: TREATMENT_CODE 
See Appendix D 
Dialysis vintage CORR Dataset: RECIPIENT_TREATMENT 






 Acute care (insttype = ‘AP’ or ‘AT’) 
Diagnosis Type (dxtype) 
 All (alldx) 


















 Acute care (insttype = ‘AP’ or ‘AT’) 




 All (alldx) 











 Acute care (insttype = ‘AP’ or ‘AT’) 
Diagnosis Type (dxtype) 
 All (alldx) 










 Acute care (insttype = ‘AP’ or ‘AT’) 















 Acute care (insttype = ‘AP’ or ‘AT’) 












 Acute care (insttype = ‘AP’ or ‘AT’) 
Diagnosis Type (dxtype) 
 All (alldx) 














 Acute care (insttype = ‘AP’ or ‘AT’) 
Diagnosis Type (dxtype) 
 All (alldx) 







Patients with hypertension are those that have evidence 
of two OHIP claims for hypertension OR one 
hospitalization with a diagnosis of hypertension within the 







 Acute care (insttype = ‘AP’ or ‘AT’) 
Diagnosis Type (dxtype) 
 All (alldx) 







Patient with diabetes are those that have evidence of two 
OHIP claims for diabetes OR one hospitalization with a 









 Acute care (insttype = ‘AP’ or ‘AT’) 
Diagnosis Type (dxtype) 
 All (alldx) 




Cardiac Testing Database(s) Codes 




 Acute care (insttype = ‘AP’ or ‘AT’) 














 Acute care (insttype = ‘AP’ or ‘AT’) 












 Acute care (insttype = ‘AP’ or ‘AT’) 














 Acute care (insttype = ‘AP’ or ‘AT’) 












 Acute care (insttype = ‘AP’ or ‘AT’) 

















Appendix C: CORR Codes for Primary Cause of End-Stage Renal Disease 
 
Glomerulonephritis/Autoimmune Diseases 
05 Mesangial proliferative glomerulonephritis  
06 Minimal lesion glomerulonephritis  
07 Post-strep glomerulonephritis  
08 Rapidly progressive glomerulonephritis  
09 Focal glomerulosclerosis - adults  
10 Glomerulonephritis, histologically NOT examined  
11 Severe nephrotic syndrome with focal sclerosis (paed.) 
12 IgA nephropathy - proven by immunofluorescence (not code 85)  
13 Dense deposit disease - proven by immunofluorescence and/or electron microscopy (MPGN type II)  
14 Membranous nephropathy  
15 Membranoproliferative mesangiocapillary glomerulonephritis (MPGN type I)  
16 Idiopathic crescentic glomerulonephritis (diffuse proliferative)  
17 17 - Congenital Nephrosis/Cong.Nephrotic Syndrome (Paed.) 
19 Glomerulonephritis, histologically examined - specify  
73 Polyarteritis  
74 Wegener’s granulomatosis  
84 Lupus erythematosus  
85 Henoch-Schõnlein purpura  
86 Goodpasture syndrome  
88 Hemolytic uremic syndrome (Moschcowitz syndrome)  
Cystic Kidney Disease 
40 Cystic kidney disease, type unspecified  
41 Polycystic kidneys, adult type (dominant)  
42 Polycystic kidneys, infantile and juvenile types (recessive)  
43 Medullary cystic disease, including nephronophthisis  
49 Cystic kidney disease, other type - specify  
Diabetes  
80 Diabetic nephropathy associated with type 1  
81 Diabetic nephropathy associated with type 2  
Renal Vascular Disease  
70 Renal vascular disease, type unspecified  
71 Malignant hypertension (no primary renal disease)  
72 Renal vascular disease due to hypertension (no primary renal disease)  
79 Renal vascular disease, classified (nephrosclerosis, renal vascular thrombosis)  
Other  
20 Pyelonephritis/interstitial nephritis, cause not specified  
21 Pyelonephritis/interstitial nephritis associated with neurogenic bladder  
22 
Pyelonephritis/interstitial nephritis due to congenital obstructive uropathy with or without 
vesicoureteric reflux  
63 
 
23 Pyelonephritis/interstitial nephritis due to acquired obstructive uropathy - specify  
24 Pyelonephritis/interstitial nephritis due to vesicoureteric reflux without obstruction  
25 Pyelonephritis/interstitial nephritis due to urolithiasis  
29 Pyelonephritis, other causes  
30 Nephropathy caused by drugs or nephrotoxic agents, cause not specified  
31 Nephropathy due to analgesic drugs  
32 Nephropathy due to cisplatin  
33 Nephropathy due to Cyclosporin A  
39 Nephropathy caused by other specific drug - specify  
50 Hereditary familial nephropathy, type unspecified  
51 Hereditary nephritis with nerve deafness (Alport syndrome)  
52 Cystinosis  
53 Oxalosis  
54 Fabry disease  
55 DRASH syndrome  
56 Sickle cell nephropathy  
57 Wilms’ tumour  
58 Posterior urethral valves  
59 Hereditary nephropathy, other - specify  
60 Congenital renal hypoplasia - specify  
61 Oligomeganephronic hypoplasia  
62 Segmental renal hypoplasia (Ask-Upmark kidney)  
63 Congenital renal dysplasia with or without urinary tract malformation  
66 Syndrome of agenesis of abdominal muscles (prune belly syndrome)  
78 Atheroembolic renal disease  
82 Multiple myeloma  
83 Amyloid  
87 Scleroderma  
89 Multi-system disease, other - specify  
90 Cortical or acute tubular necrosis  
91 Tuberculosis  
92 Gout  
93 Nephrocalcinosis and hypercalcemic nephropathy  
94 Balkan nephropathy  
95 Kidney tumour  
96 Traumatic or surgical loss of kidney  
97 HIV nephropathy  
99 Other identified renal disorders - specify  
Unknown 




Appendix D: CORR Codes for Treatment Codes for Dialysis 
 
Hemodialysis 
111 1 - Acute Care Hospital, 1 - Conventional Haemodialysis, 1 - Total Care 
112 1 - Acute Care Hospital, 1 - Conventional Haemodialysis, 2 - Limited Self Care 
113 1 - Acute Care Hospital, 1 - Conventional Haemodialysis, 3 - Total Self Care 
121 1 - Acute Care Hospital, 2 - Short Daily Haemodialysis, 1 - Total Care 
122 1 - Acute Care Hospital, 2 - Short Daily Haemodialysis, 2 - Limited Self Care 
123 1 - Acute Care Hospital, 2 - Short Daily Haemodialysis, 3 - Total Self Care 
131 1 - Acute Care Hospital, 3 - Slow Nocturnal Haemodialysis, 1 - Total Care 
132 1 - Acute Care Hospital, 3 - Slow Nocturnal Haemodialysis, 2 - Limited Self Care 
133 1 - Acute Care Hospital, 3 - Slow Nocturnal Haemodialysis, 3 - Total Self Care 
211 2 - Chronic Care Hospital, 1 - Conventional Haemodialysis, 1 - Total Care 
221 2 - Chronic Care Hospital, 2 - Short Daily Haemodialysis, 1 - Total Care 
231 2 - Chronic Care Hospital, 3 - Slow Nocturnal Haemodialysis, 1 - Total Care 
311 3 - Community Centre, 1 - Conventional Haemodialysis, 1 - Total Care 
312 3 - Community Centre, 1 - Conventional Haemodialysis, 2 - Limited Self Care 
313 3 - Community Centre, 1 - Conventional Haemodialysis, 3 - Total Self Care 
321 3 - Community Centre, 2 - Short Daily Haemodialysis, 1 - Total Care 
322 3 - Community Centre, 2 - Short Daily Haemodialysis, 2 - Limited Self Care 
323 3 - Community Centre, 2 - Short Daily Haemodialysis, 3 - Total Self Care 
331 3 - Community Centre, 3 - Slow Nocturnal Haemodialysis, 1 - Total Care 
332 3 - Community Centre, 3 - Slow Nocturnal Haemodialysis, 2 - Limited Self Care 
333 3 - Community Centre, 3 - Slow Nocturnal Haemodialysis, 3 - Total Self Care 
413 4 - Home, 1 - Conventional Haemodialysis, 3 - Total Self Care 
423 4 - Home, 2 - Short Daily Haemodialysis, 3 - Total Self Care 
433 4 - Home, 3 - Slow Nocturnal Haemodialysis, 3 - Total Self Care 
Peritoneal Dialysis 
141 1 - Acute Care Hospital, 4 - CAPD, 1 - Total Care 
151 1 - Acute Care Hospital, 5 - APD, 1 - Total Care 
152 1 - Acute Care Hospital, 5 - APD, 2 - Limited Self Care 
241 2 - Chronic Care Hospital, 4 - CAPD, 1 - Total Care 
242 2 - Chronic Care Hospital, 4 - CAPD, 2 - Limited Self Care 
251 2 - Chronic Care Hospital, 5 - APD, 1 - Total Care 
252 2 - Chronic Care Hospital, 5 - APD, 2 - Limited Self Care 
443 4 - Home, 4 - CAPD, 3 - Total Self Care 
453 4 - Home, 5 - APD, 3 - Total Self Care 
Other 







Appendix E: Diagnostic Codes for Outcome Variables 
 
CIHI-DAD 
Diagnosis Type (dxtype) 
 Most responsible diagnosis (M)  
(except where indicated e.g. alldx for 30-day outcome of acute MI and ischemic stroke) 
 
Outcome Variable Database(s) Codes 
Death RPDB Vital status field 
Myocardial infarction CIHI–diagnostic 
 
 















Cardiac testing CIHI-procedure 
OHIP-procedure 
See Appendix B 
 
 















(a) Indicate the study’s design with a commonly used 
term in the title or the abstract 
Abstract 
(b) Provide in the abstract an informative and balanced 






Explain the scientific background and rationale for the 
investigation being reported 
Introduction 
Objectives 3 




Study design 4 Present key elements of study design early in the paper Methods 
Setting 5 
Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-up, 
and data collection 
Methods 
Participants 6 
(a) Give the eligibility criteria, and the sources and 
methods of selection of participants. Describe methods 
of follow-up 
Methods 
(b) For matched studies, give matching criteria and 
number of exposed and unexposed 
Methods 
Variables 7 
Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 






For each variable of interest, give sources of data and 
details of methods of assessment (measurement). 
Describe comparability of assessment methods if there 
is more than one group 
Methods 
Appendix 3 
Bias 9 Describe any efforts to address potential sources of bias Methods 






Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were 





(a) Describe all statistical methods, including those used 
to control for confounding 
Methods 




(c) Explain how missing data were addressed Methods 
(d) If applicable, explain how loss to follow-up was 
addressed 
Not applicable 
(e) Describe any sensitivity analyses Not applicable 
Results 
Participants 13 
(a) Report numbers of individuals at each stage of 
study—e.g. numbers potentially eligible, examined for 
eligibility, confirmed eligible, included in the study, 
completing follow-up, and analyzed 
Results 
Figure 1 
(b) Give reasons for non-participation at each stage Figure 1 
(c) Consider use of a flow diagram Figure 1 
Descriptive data 14 
(a) Give characteristics of study participants (e.g. 
demographic, clinical, social) and information on 




(b) Indicate number of participants with missing data for 
each variable of interest 
Table 2 
(c) Summarize follow-up time (e.g. average and total 
amount) 
Results 
Outcome data 15 
Report numbers of outcome events or summary 




Main results 16 
(a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision (e.g. 
95% confidence interval). Make clear which 





(b) Report category boundaries when continuous 
variables were categorized 
Table 1 
(c) If relevant, consider translating estimates of relative 
risk into absolute risk for a meaningful time period 
Not applicable 
Other analyses 17 
Report other analyses done—e.g. analyses of subgroups 
and interactions, and sensitivity analyses 
Results 
Discussion 
Key results 18 




Discuss limitations of the study, taking into account 
sources of potential bias or imprecision. Discuss both 
direction and magnitude of any potential bias 
Discussion 
Interpretation 20 Give a cautious overall interpretation of results Discussion 
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considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other relevant 
evidence 
Generalizability 21 





Give the source of funding and the role of the funders 
for the present study and, if applicable, for the original 





Appendix 3: Databases and coding definitions. 
















ICD-9: V42.0, 996.81 
 
ICD-10: N16.5, T86.1, Z94.0 
 




OHIP: E762, E769, E771, G347, G348, G408, G409, G412, 
S434, S435, Z631 
 
Treatment_code: 171, 181 












ICD-9: V45.1, V56.0, V56.8, 996.73 
 
ICD-10: T82.4, Y60.2, Y61.2, Y62.2, Y84.1, Z49, Z99.2 
 
CCP: 51.27, 51.42, 51.43, 51.95, 66.98 
 
CCI: 1JM76NC, 1JM76NCXXN, 1KG76MZXXA, 
1KG76MZXXN, 1KY76, 1PZ21, 1OT53DATS, 
1OT53HATS, 1OT53LATS, 1SY55LAFT, 7SC59QD 
 
OHIP: G082, G083, G085, G090, G091, G092, G093, G094, 
G095, G096, G099, G294, G295, G323, G324, G325, G326, 
G327, G330, G331, G332, G333, G336, G860, G861, G862, 
G863, G864, G865, G866, H540, H740, R825, R826, R827, 
R833, R840, R841, R843, R848, R849, R850, R851, R852, 
R853, R854, R885, R941, R942, R943, R944, R945, R946, 









ICD-9: 250.4, 403.0, 403.1, 403.9, 404.0, 404.1, 404.9, 585, 
586, 588.8, 588.9 
 
ICD-10: E10.2, E11.2, E13.2, E14.2, I12, I13, N08, N18, N19 
 
OHIP: 403, 585 
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Other: 08, 09, 10, 11, 99 
Unknown: 98 
Baseline Characteristics – Kidney-Related Characteristics 
Transplant date CORR  
Cause of ESRD CORR Primary_diagnosis_kidney:  
Glomerulonephritis/Auto-immune disease: 05, 06, 07, 08, 09, 
10, 11, 12, 13, 14, 15, 16, 17, 19, 73, 74, 84, 85, 86, 88 
Diabetes: 80, 81 
Cystic kidney disease: 40, 41, 42, 43, 49 
Renal vascular disease: 70, 71, 72, 79 
Other: 20, 21, 22, 23, 24, 25, 29, 30, 31, 32, 33, 39, 50, 51, 52, 
53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 66, 78, 82, 83, 87, 
89, 90, 91, 92, 93, 94, 95, 96, 97, 99 
Unknown: 00, 98 
Donor type CORR Donor_type_code: 
Living: 02, 03, 04, 05, 06, 07, 10, 12, 15 
Deceased: 01 
Unknown/Out-of-country transplant: 98 
Dialysis modality CORR Treatment_code: 
Hemodialysis: 111, 112, 113, 121, 122, 123, 131, 132, 133, 
211, 221, 231, 311, 312, 313, 321, 322, 323, 331, 332, 333, 
413, 423, 433 
Peritoneal dialysis: 141, 151, 152, 241, 242, 251, 252, 443, 
453 
Other: 060 











OHIP-procedurea OHIP: G082, G083, G085, G090, G091, G092, G093, G094, 
G095, G096, G294, G295, G323, G325, G326, G330, G331, 
G332, G333, G860, G861, G862, G863, G864, G865, G866, 
H540, H740, R849 














ICD-9: 410, 411, 412 
 
ICD-10: I21, I22, T82.2, Z95.5 
 
CCP: 48.01, 48.02, 48.03, 48.04, 48.05, 48.1, 48.2, 48.3 
 
CCI: 1IJ50, 1IJ76 
 
OHIP: 410, 412 
 
OHIP: E646, E651, E652, E654, E655, G298, R741, R742, 






ICD-9: 401, 402, 403, 404, 405 
 
ICD-10: I10, I11, I12, I13, I15 
 




























CCP: 48.02, 48.03, 48.09 
 
CCI: 1IJ50, 1IJ54GQAZ, 1IJ57GQ 
 
OHIP: G262, G298, Z434 
CABG surgery CIHI-procedure 
 
CIHI-procedure 








OHIP: E645, E646, E652, E654, R742, R743 












ICD-9: 425, 428, 514, 518.4 
 
ICD-10: I25.5, I50.0, I50.1, I50.9, J81 
 
CCP: 49.61, 49.62, 49.63, 49.64 
 









ICD-9: 362.3, 430, 431, 432, 434, 435, 436 
 
ICD-10: G45.0, G45.1, G45.2, G45.3, G45.8, G45.9, H34.0, 
H34.1, I60.0, I60.1, I60.2, I60.3, I60.4, I60.5, I60.6, I60.7, 
I60.9, I61, I62, I63.0, I63.1, I63.2, I63.3, I63.4, I63.5, I63.8, 
I63.9, I64 
Baseline Characteristics – Cardiovascular Investigations 









OHIP: G311, G320, G647, G648, G649, G650, G651, G652, 
G653, G654, G655, G656, G657, G658, G659, G660, G661, 











OHIP: G560, G561, G562, G566, G567, G568, G570, G571, 
G572, G574, G575, G576, G577, G578, G581 





CCP: 03.41, 03.42, 03.43, 03.44, 06.05 
 
CCI: 2HZ08, 3IP70 
 
OHIP: G111, G112, G174, G315, G319, G582, G583, G584, 
73 
 








CCP: 48.92, 48.93, 48.94, 48.95, 48.96, 48.97, 48.98 
 
CCI: 3IP10, 3IS10 
 










CCI: 3JE30, 3JG30 
 
OHIP: J190, J191, J201, J490, J491, J492, J501 
Outcome Measurements Validityc,d 








For ICD-10 codes:e 
Sensitivity: 89% 
PPV: 87% 
PCI (71) CIHI-procedure 
 
OHIP-procedurea 
As above For CCI codes: 
PPV: 94-96% 
CABG (71) CIHI-procedure 
 
OHIP-procedurea 








ICD-9: 434, 436 
 
 
ICD-10: H34.1, I63.0, I63.1, I63.2, 
I63.3, I63.4, I63.5, I63.8, I63.9, I64 







As above  
a Approximately 95% of Ontario physicians operate under the fee for service payment structure of the 
Ontario Health Insurance Plan (OHIP). The sensitivity and positive predictive value of these procedure 
codes is expected to be high, as shown with other service payments.(73) Other studies have reported the 
value of using physician billing data in combination with other administrative healthcare data to 
improve the identification of relevant procedures.(74) 
74 
 
b Defined as evidence of 2 OHIP claims or 1 hospitalization with a diagnostic claim within the 3-year 
look-back window. 
c Information regarding specificity and negative predictive value is omitted. In almost all instances 
these parameters were high and precise because of the low underlying prevalence of the diagnoses or 
procedures in the dataset. 
d Validation performed against the following reference standards: chart review,(68) patient registry,(69) 
chart abstraction and recoding.(70–72) Diagnostic conditions were considered present in the discharge 
abstract for any hospitalization if it was listed as the primary reason for the majority of length of 
hospital stay. 
e Added ICD-10 code I22 (subsequent myocardial infarction). 
Abbreviations: CABG, coronary artery bypass graft; CCI, Canadian Classification of Health 
Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures; CIHI, 
Canadian Institute for Health Information; CORR, Canadian Organ Replacement Register; ESRD, end-
stage renal disease; ICD-9; International Classification of Diseases, 9th Revision; ICD-10, International 
Classification of Diseases, 10th Revision; OHIP, Ontario Health Insurance Plan; PCI, percutaneous 
coronary intervention; PPV, positive predictive value; RPDB, Registered Persons Database; TIA, 
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